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Abstract
We describe an autosomal recessive heterogeneous congenital myopathy in a large consanguineous family. The disease is
characterized by variable severity, progressive course in 3 of 4 patients, myopathic face without ophthalmoplegia and
proximal muscle weakness. Absence of cores was noted in all patients. Genome wide linkage analysis revealed a single locus
on chromosome 19q13 with Zmax = 3.86 at h= 0.0 and homozygosity of the polymorphic markers at this locus in patients.
Direct sequencing of the main candidate gene within the candidate region, RYR1, was performed. A novel homozygous A to
G nucleotide substitution (p.Y3016C) within exon 60 of the RYR1 gene was found in patients. ARMS PCR was used to screen
for the mutation in all available family members and in an additional 150 healthy individuals. This procedure confirmed
sequence analysis and did not reveal the A to G mutation (p.Y3016C) in 300 chromosomes from healthy individuals.
Functional analysis on EBV immortalized cell lines showed no effect of the mutation on RyR1 pharmacological activation or
the content of intracellular Ca2+ stores. Western blot analysis demonstrated a significant reduction of the RyR1 protein in the
patient’s muscle concomitant with a reduction of the DHPRa1.1 protein. This novel mutation resulting in RyR1 protein
decrease causes heterogeneous clinical presentation, including slow progression course and absence of centrally localized
cores on muscle biopsy. We suggest that RYR1 related myopathy should be considered in a wide variety of clinical and
pathological presentation in childhood myopathies.
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Introduction
Congenital myopathies are a heterogeneous group of neuro-
muscular disorders that can be subdivided, based on the
predominant pathologic features observed on muscle biopsy, into:
myopathies with protein accumulations, myopathies with cores,
myopathies with central nuclei and myopathies with fibre size
disproportion [1,2]. While mutations in many genes may lead to
similar pathological features, mutations in a single gene may also
result in different muscle pathologies. Indeed, mutations in the
RYR1 gene can lead to several clinical phenotypes: Malignant
hyperthermia susceptibility including King-Denborough syn-
drome (MHS, pharmacogenetic disorder of skeletal muscle,
MIM#145600), Central Core Disease (CCD, MIM#117000), as
well as some forms of Multi minicore disease (MmD,
MIM#255320), Centronuclear myopathy (CNM, MIM#
160150), congenital fiber type disproportion (CFTD,
MIM#255310) and other rare atypical myopathies (see [3] for
review).
The ryanodine receptor 1 gene (RYR1) maps to chromosome
19q13.2 and is composed of 106 exons [4,5]. It encodes one of the
largest mammalian proteins (5038 amino acids, 565,176 KDa) that
acts as a calcium release channel. The protein is mainly expressed
in skeletal muscles where it plays a central role in excitation-
contraction coupling, the process by which an electrical signal
sensed by the dihydropyridine receptor (DHPR) located on the
transverse tubules, is converted into a chemical signal, i.e. Ca2+,
release from the sarcoplasmic reticulum [4].
The active channel is composed of four identical RyR1
homotetramers which assemble into a functional channel permit-
ting the release of calcium from the sarcoplasmic reticulum stores
[6,7]. Many proteins have been reported to interact with the
RyR1 (the alpha1 subunit of the DHPR, calmodulin, S100,
FKBP12, triadin, homer) and to modulate its activity (see [8] for
review).
So far, more than 300 mutations (source Human Gene
Mutation Database, HGMD) in RYR1 have been associated with
various forms of neuromuscular disorders: MHS and CCD are
mostly inherited in a dominant way whereas MmD is inherited
in a recessive way. Interestingly, many dominant mutations
linked to MH appear to cluster in the cytoplasmic N-terminal
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and central region (commonly called hot spot region 1 & 2
respectively) while mutations found in patients with CCD are
predominantly localized to the C-terminal hydrophobic region
(hot spot 3). On the contrary, recessive MmD mutations are
spread all over the gene [9]. These observations emphasize one
aspect of the complex genotype-phenotype correlations associated
with RYR1 mutations.
In the present study we describe an autosomal recessive
myopathy in a large consanguineous family. The disease in this
family is characterized by myopathic facial features, proximal limb
muscle weakness and delay in motor milestones in all patients.
However, clinical and pathological heterogeneity was noted within
the family. Neonatal onset associated with no ambulation and
central nuclei on muscle biopsy was found in one patient. Slowly
progressive motor decline and localized fibrosis on muscle
pathology in three patients resembled muscular dystrophy and
were associated with delay in the diagnosis of this family. Genome
wide linkage analysis revealed a single locus on chromosome
19q13. A homozygous A to G nucleotide substitution
(c.9047A.G) resulting in the p.Y3016C substitution within exon
60 of the RYR1 gene was found in the affected patients. Using the
previously established method of Ca2+ homeostasis in EBV
immortalized cells [10,11] from affected and non affected family
members, we show that the mutation we identify does not cause a
shift in sensitivity of the RyR1 to activating stimuli or lead to a
lower content of rapidly releasable Ca2+ from intracellular stores.
Indeed the mutation did not seem to affect Ca2+ homeostasis per
se, but rather lead to a decrease in protein content in muscle from
the patient as determined by Western blotting. Thus the
pathogenicity of the mutation is linked to protein expression
which can indirectly affect excitation-contraction coupling by
decreasing the amount of Ca2+ released because of the reduced
expression of RyR1 Ca2+ release channels.
Subjects/Materials and Methods
Patients
Blood samples were obtained from affected and unaffected
individuals after informed written consent. For minors/children
participants, a written informed consent was obtained from their
parents. DNA was extracted by using standard protocols. This
study was approved by the Hadassah Ethical Review Committee.
Pathological studies
Muscle biopsy specimens were received fresh without fixation
and processed according to standard protocol. Most of the samples
were snap-frozen in liquid nitrogen and cryo-preserved at 280uC.
Part of the samples were fixed in formalin and embedded in a
paraffin block while the remaining portions, if available, were fixed
in glutaraldehyde and embedded in epoxy-resin. Paraffin sections
were stained with hematoxylin and eosin (H&E) and frozen
sections were stained according to standard protocols with H&E,
modified Gomori-trichrome, enzyme-histochemical studies
(ATPase 9.4, 4.3; NADH; SDH/COX; PAS; PAS+D; ORO)
and immunohistochemical stains for fast and slow myosin. In
addition, frozen sections were stained for muscle membrane
proteins including spectrin, dystrophin (dys1, dys2, dys3),
utrophin, sarcoglycans (alpha, beta, gamma, delta), laminin beta-
1, merosin (300KD, 80KD), dysferlin, caveolin-3, perlecan,
collagen IV, collagen VI and for the nuclear protein emerin,
according to standard staining protocols with commercially
available antibodies.
Genome wide linkage analysis
Whole genome screening was performed using 250K SNP
microarray (Affymetrix) following a standard protocol. Multipoint
linkage analysis of SNP data applied to the whole genome has
been performed using Alohomora [12] and Merlin softwares [13]
with the following parameters: autosomal recessive inheritance,
100% penetrance and disease gene frequency in the population of
1:10 000.
Sequence Analysis and screening of the mutation
RYR1 gene sequencing was performed in a reference center
(Laboratoire de biochimie et genetique moleculaire, CHU-
Grenoble, France). All 106 coding exons were sequenced from
genomic DNA from an affected individual (IV.15) and compared
to the published sequences. The nomenclature was based on the
reference sequence RYR1 (GRCh37.p5 assembly, genome build
37.3, NM_000540.2), with nucleotide number 1 corresponding to
the first base of the translation initiation codon.
Table 1. Primers used for sequencing and mutation analyses.
Primer Sequence (5’-3’)
Primer Forward Reverse
RYR1-Seq acccctcattggaccctttatc ttgcaggagacggtcagtacc
MUT acttcaccaaccactgcctccg ttgcaggagacggtcagtacc
WT acttcaccaaccactgcctcca ttgcaggagacggtcagtacc
doi:10.1371/journal.pone.0069296.t001
Table 2. Clinical features and laboratory findings in the patients with myopathy.
Patient Sex
Current age
(years) Onset CK Weakness
Muscle biopsy
findings Motor function Ocular Scoliosis
Patient 1 (IV.15) F 30 Birth N Face, Neck, limb
girdle
Central nuclei wheelchair-bound – Y
Patient 2 (V.28) M 17 18 months N Face, Neck, limb
girdle
FSV, IDN, EF Walking – No
Patient 3 (V.31) M 10 6 years N Face, Neck, limb
girdle
FSV, IDN, EF Walking – Y
Patient 4 (V.36) M 9 4 years N Face, Neck, limb
girdle
FSV, IDN, EF Walking – No
F: female; M: male; N: normal; FSV: fiber-size variation; IDN: internally-displaced nuclei; EF: endomysial fibrosis; Y:yes; No: No.
doi:10.1371/journal.pone.0069296.t002
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The segregation of the mutation was checked in the pedigree by
Sanger sequencing. Briefly, PCR primer pairs were designed from
genomic DNA to amplify exon 60 of the isoform 1 of the RYR1
gene including the flanking exon-intron junctions (Table 1). The
purified PCR products were sequenced using the forward and
reverse primers of each amplicon using standard Sanger sequenc-
ing protocol.
The ARMS PCR (Amplification Refractory Mutation System)
reaction was performed in 50 ml final volume with 1.6 mM
MgCl2, 0.5 U BIOTAQ
TM DNA Polymerase (Bioline), 0.2 mM
each primer and 50 ng DNA. Amplification parameters were:
94uC for 5 min, 30 cycles (95uC/15 sec., Tm/15 sec., 72uC/
15 sec.), and 5 min. at 72uC, in an ABI 2720 Thermal Cycler
(Applied Biosystem).
Cell Culture and intracellular measurements
Lymphoblastoid cell lines. Mononuclear cells were isolated
from peripheral blood leukocytes and transformed with EBV
Figure 1. Linkage analysis of the family suffering from autosomal recessive atypical congenital myopathy. (A) Pedigree of the family.
Filled and unfilled symbols represent affected and unaffected individuals, respectively. The arrows denote individuals whose DNA samples were
analyzed by SNP250K. (B) Multipoint linkage analysis using SNP data showing LOD score Zmax=3.86 at h= 0.0 on chromosome 19q13. X-axis: genetic
distance in cM., Y-axis: Lod score.
doi:10.1371/journal.pone.0069296.g001
Figure 2. Histological analysis of patients muscle biopsies. Frozen sections of 3 cases (V28, V31 & V36) that were available for pathological
review display non-specific dystrophic-like changes, consistent with muscular dystrophy. H&E stained sections (A–C) show marked variation in
myofiber-diameter, in random distribution. The number of internally displaced nuclei (white arrows) is markedly increased. There are no clear-cut
signs of necrosis, regeneration or any other specific structural change in the myofibers. There is focal endomysial fibrosis (black arrows). There is no
inflammatory infiltrate. The blood vessels are unremarkable. NADH histochemical stain (D–F) is not showing significant changes in the
cytoarchitecture, except for occasional moth-eaten-like fibers (red arrows) and overstaining of atrophic fibers (yellow fibers). (Original magnification
640; Bars = 50 mm).
doi:10.1371/journal.pone.0069296.g002
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according to the protocol of Neitzel [14]. Cells were cultured in
RPMI medium supplemented with 10 % fetal calf serum, 2 mM
L-glutamine and 100 Units of penicillin and streptomycin.
Intracellular Ca2+ measurements. Changes in the intra-
cellular calcium concentration of the lymphoblastoid cells were
monitored with the fluorescent calcium indicator fura-2/AM
(Invitrogen F1201) as previously described [10]. Fura-2 loaded
cells (1.56106/ml; final fura-2 concentration 5 mM) were washed
once by centrifugation, resuspended in Ca2+-free Krebs–Ringer
medium containing 0.5mM EGTA and placed in a cuvette
thermostated at 37uC. Fluorescence changes (ratio 340/380 nm)
were measured in a spectrofluorimeter (Perkin Elmer 50B)
equipped with a magnetic stirrer. All measurements were made
in Ca2+-free Krebs–Ringer buffer containing 0.5mM EGTA
(Sigma K4002). Experiments were performed at least four times
on three different days.
Western Blotting
Cryo-preserved muscle from patient V.28 was homogenized
and lysed at 4uC in lysis buffer (100 mM Tris-HCl, pH 7.4, 1%
Nonidet P40, 20 mM b mercapto-ethanol, 1 mM ethylene
diamine tetra acetate) freshly supplemented with the protease
inhibitor 1 mM phenyl-methane-sulfonyl-fluoride. The protein
concentration of the lysates was determined using the Bradford
quantification method. Lysates equivalent to 50 mg of total protein
were fractionated by denaturing 6% polyacrylamide gel electro-
phoresis and transferred to nitrocellulose by standard electroblot-
ting techniques. Western blots were probed with anti-RyR1
(Thermo Scientific mAb 34C MA3-925), anti-Cav1.1 (Santa Cruz
sc-8160) and anti -Myosin (Millipore MAB1628) antibodies
followed by the appropriate secondary conjugate and developed
using the Super Signal chemiluminescence kit (Thermo scientific
34076) as previously described [15].
Statistical analysis
Statistical analysis was performed using Student’s t test for
paired samples or ANOVA when more than two groups were
compared followed by the Bonferroni post hoc test. Origin
computer program (Microcal Software, Inc., Northampton, MA,
USA) was used for statistical analysis and dose response curve
generation. Results are expressed as mean value (6 SEM) of n
results, where n stands for the number of measurements.
Results
Patients’ description
Description of the patients and their family members is
presented in Table 2.
Patient 1 (IV.15) is the first child of consanguineous first
cousins of Muslim origin (Fig 1A). She was born after normal
pregnancy at term by vacuum delivery. Severe hypotonia was
noted after birth. Gross motor development was slow. At age
6 months, the patient could not lift her head in prone position, and
at the age of 18 months, she only stood with support. She never
achieved independent walking. Her cognitive development was
normal. Over the years, the patient had frequent hospitalizations
for upper respiratory and pulmonary infections. Neurological
examination at 10 years of age demonstrated decrease in muscle
mass, low body weight, myopathic long face and proximal
weakness. Electromyography was normal. Muscle biopsy at the
age of 18 months showed variation in fiber size with central nuclei
and several atrophic fibers (unfortunately the slides of this muscle
biopsy are unavailable). Plasma creatine kinase levels were normal.
Diagnosis at the time was centronuclear myopathy. The patient
returned to our clinic at the age of 23 years. She was a university
graduate. On a recent examination, her face was long and thin,
with preserved facial expression. There was no limitation of
extraocular movements. There was general muscle wasting and
weakness most prominent in neck extensors and flexors (MRC 3/
5), deltoid (MRC 3/5) and hip girdle (MRC 2/5). Tendon reflexes
were elicited in the upper limbs. Her scoliosis had worsened and a
CXR revealed lumbar scoliosis of 30u to the left and subluxation of
the right hip joint.
Patient 2 (V.28) is the first cousin of patient 1 (IV.15). He was
born to consanguineous cousins as part of a dizygotic twin
pregnancy with uneventful delivery (Fig 1A). His mother noticed
slight hypotonia and gross developmental delay compared to his
twin brother. The patient walked independently at age 15 months
but later could not climb stairs and required support to rise from a
Figure 3. Analysis of RYR1 at the DNA level in patients and controls. (A) Sequence of the RYR1 gene revealed a homozygous A to G
nucleotide substitution leading to an amino acid change (p.Y3016C) within exon 60 in patient (arrow). (B) Analysis of the mutation in family members
and control. Left panel: PCR amplification products of RYR1 from exon -60 to intron-60 using primers specific to the mutated allele (MUT Primers,
product size = 210 bp). Right panel: PCR amplification products of RYR1 from exon-60 to intron – 60 using primers specific to wild type allele (WT
Primers, product size = 210 bp). This test confirms the cosegregation of the RYR1 mutation with the phenotype and haplotypes in the family. C:
control. Affected individuals are underlined.
doi:10.1371/journal.pone.0069296.g003
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sitting position. He fell frequently. Intellectual performance was
good. Laboratory results showed normal level of plasma creatine
kinase. Electromyography revealed no abnormalities. Quadiceps
muscle biopsy (Fig 2A & 2D) showed variable fiber-size
distribution and an increase of internal nuclei, usually several
per myofiber rather than one central nucleus. There were no
clear-cut signs of necrosis, regeneration or any other specific
structural change in the myofibers. There was however, focal
endomysial fibrosis with no inflammatory infiltrate. These findings
including focal excessive endomysial fibrosis were interpreted as
suggestive of muscular dystrophy. Enzyme-histochemical studies
did not reveal significant changes except for occasional moth-
eaten-like fibers and overstaining of atrophic fibers on NADH
stain. Semi thin sections and electron microscopy did not show any
cores, minicores or any other significant change except for focal
abundant fibrosis. Immunostains for muscle membrane proteins
and for emerin were interpreted as normal (data not shown).
Molecular testing for selenoprotein and FKRP was negative. On a
recent examination at the age of 13 years, a thin long face was
observed with no ptosis or ophthalmoplegia. There was general
muscle wasting and weakness mainly in neck flexion and extension
and hip and shoulder girdles (MRC 3+). Waddling gait and
hyperlordosis were observed with positive Gower’s sign. The
patient is still ambulant and the parents reported slowly
progressive weakness. Reduced deep tendon reflexes were elicited
at the patellar tendons.
Patient 3 (V.31) presented to our clinic at the age of 6 years
because of maternal concerns about gross motor impairment,
similar to what was found in his older brother (patient 2, V.28,
Fig 1A). The child sat at the age of 7 months and walked
independently by age 14 months with frequent falls. Perinatal
history was uneventful. Physical examination demonstrated
myopathic face with normal eye movements. Strength was 3+/5
in lower limb proximal muscles and 42/5 in proximal upper
limbs. Shoulder atrophy and early scoliosis were observed.
Waddling gait and near positive Gowers’ sign were noted. Slowly
progressive course of the disease was reported. The muscle biopsy
including electron microscopy findings (Fig 2C and 2F) were
similar to those described for patient number 2, except for a
relative increase of type 1 fibers.
Patient 4 (V.36) is the youngest of 4 siblings, born to
consanguineous cousins. He is the first cousin of patients 1, 2
and 3 (IV.15, V.28, and V.31, Fig 1A). He was born at 32 weeks
gestation via caesarian section, birth weight was 900 grams.
Perinatal period was remarkable for respiratory distress syndrome
which required mechanical ventilation. He was discharged from
the NICU after 50 days. He achieved independent walking at
18 months of age. Gross and fine motor impairment were initially
attributed to prematurity. On presentation to our clinic at the age
of 4 years, neurological examination revealed myopathic face,
waddling gait, and difficulty in climbing stairs. The parents
reported slowly progressive weakness. Muscle biopsy findings
(Fig 2B and 2E) were similar to those described for patient number
2. Electron-microscopy did not reveal core-like structures or any
other specific abnormalities (data not shown). Thereafter, we were
informed of yet another family member (patient V26) with similar
features who was followed at another medical center.
Figure 4. Ca2+ homeostasis analysis in EBV immortalized cells
from affected, non affected family members and controls. (A)
Comparison of the resting [Ca2+]i shows lower [Ca
2+]i in cells carrying
the mutation compared with control cells. **P,0.001 ANOVA followed
by the Bonferroni post hoc test (B) The thapsigargin-induced Ca2+
release in lymphoblastoid B cells are represented by the difference
between the resting [Ca2+]i and the [Ca
2+]i after addition of 400 nM
thapsigargin. No significant differences between cells carrying the
homozygous or heterozygous p.Y3016C mutation were found. (C)
Dose-dependent 4-chloro-m-cresol induced Ca2+ release in lympho-
blastoid B cells. No significant changes were evident at concentrations
,750 mM though at higher concentrations cells carrying the heterozy-
gous and homozygous p.Y3016C substitution showed significantly
lower Ca2+ release compared to control cells ***P,0.05 (ANOVA and
Bonferroni post hoc test, P,0.05).
doi:10.1371/journal.pone.0069296.g004
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Genome wide linkage analysis
To identify the disease locus, genome wide linkage analysis was
performed using the Affymetrix 250K SNP arrays, following
standard protocol, on samples indicated by arrows (Fig 1A).
Multipoint linkage analysis of SNP data applied to the whole
genome revealed two loci on chromosome 19q13 with a maximum
LOD score Zmax=3.86 at h=0.0 (Fig 1B). The candidate regions
were 12.6 Mb and 2 Mb in size between SNP rs8107011 (physical
position 30,841,000) and rs7246771 (physical position: 43,509,033)
and between SNP rs1421673 (physical position 48,757,608) and
rs4802703 (physical position 50,884,885) respectively. The study of
the SNP genotype in the candidate regions allowed the restriction
of the region to a single locus between SNP rs2651101 (physical
position 35,424,759) and rs7246771 (physical position:
43,509,033). Indeed, homozygosity at each SNP locus was found
only within this interval for all affected individuals of the family
(available upon request). The recombinant events occurred
between rs2651101 and rs2546019 (centromeric boundary) and
between rs2189679 and rs7246771 (telomeric boundary). Linkage
and homozygosity by descent allowed the mapping of the disease
gene within this interval.
Sequence analysis and screening of the mutation
Using Map viewer (NCBI), a total of 311 genes was localized in
the candidate region. Among them, those expressed in skeletal
muscle, or encoding proteins interacting with proteins involved in
the neuromuscular system development, maintenance or diseases
in either human or mouse were selected for sequence analysis. The
RYR1 gene was regarded as the best candidate as mutations within
this gene are responsible for a growing number of myopathies as
well as for malignant hyperthermia susceptibility [16,17]. Because
of the large size of RYR1 gene (106 exons), mutation screening was
performed in a reference center. Sequence analysis of patient
(IV.15) revealed a homozygous A to G nucleotide substitution at
position 9047 leading to an amino acid change, p.Y3016C (Fig 3A).
All affected individuals or obligate carriers carried homozygous or
heterozygous mutations, respectively, demonstrating the co-
segregation of the mutation with the disease phenotype (Fig 3B).
An ARMS PCR strategy was used to screen for the mutation in all
available family members and in an additional 150 healthy
individuals, including 50 from a North Arab Israeli population.
This procedure confirmed sequence analysis and did not reveal the
A to G mutation in 300 chromosomes from healthy individuals
(data not shown).
Functional properties of cells expressing the RYR1
mutation
Although the RyR1 is mainly expressed in skeletal muscles, it
has been previously shown that it is also expressed in EBV
immortalized lymphoblastoid cells [11,18]. Thus, in order to
characterize the functional effect of the mutation, analysis was
performed on lymphoblastoid cells carrying the mutation either at
a homozygous or heterozygous level. Study of resting cytosolic
calcium concentration showed slightly but significantly lower
[Ca2+]i in cells carrying the p.Y3016C mutation at heterozygous
and homozygous states (Fig 4A). Next, the status of the
intracellular calcium stores was evaluated by addition of the
SERCA inhibitor thapsigargin. The addition of 400 nM
thapsigargin revealed that in cells carrying the p.Y3060C +/2
mutation, the ER Ca2+ stores were slightly larger. However, the
difference did not reach statistical significance when compared to
controls. No significant differences were noted in cells homozygous
for the mutation (Fig 4B). Taken together, these results indicate
that this mutation does not lead to leakage of Ca2+ from the
endoplasmic reticulum calcium stores.
The sensitivity of the RyR1 to pharmacological activation was
tested with the RyR1 agonist 4 chloro-m-cresol (4-cmc). At 4-cmc
concentrations below 750 mM, the release of Ca2+ from the cells
carrying the mutation (at the heterozygous and homozygous state)
was similar to that of control cells (Fig 4C). Furthermore,
calculation of the EC50 (50% effective concentration) showed no
significant differences between control cells and cells carrying the
mutation (p.0.05). Analysis of the complete 4-chloro-m-cresol
dose dependent curve using ANOVA followed by the Bonferroni
post hoc test revealed a significant decrease in 4-chloro-m-cresol
Ca2+ release in cells carrying the heterozygous and homozygous
p.Y3016C substitution only at concentrations .750 mM.
Western blot analysis
In some recessive RYR1 myopathies, an alteration of the RyR1
protein level has been reported in the skeletal muscles [9,19,20].
Thus, total proteins were extracted from quadriceps muscle from
patient (V.28) and control. Western Blot analysis revealed a low
level of RyR1 protein (58% decrease) for the patient carrying the
homozygous mutation compared with control (Fig 5). This
depletion was also associated with depletion of the DHPRalpha1.1
protein (68% decrease, Fig 5). The intensity of the myosin heavy
chain immunoreactive band was used as muscle specific control for
Figure 5. Effect of the pY3016C mutation on RyR1 protein expression on patient and control muscle biopsies. The western blot shows
a dramatic decrease of the RyR1 protein and of the DHPRalpha 1.1 expression in the patient’s biopsy compared to control’s biopsy (P,0.05). Protein
expression levels were quantified by densitometric analysis and normalized to the expression of myosin heavy chain. The bar plot on the right shows
the mean % protein content (6 SEM; of 3 different western blots) in biopsies from a control and patient Y3016C2/2 (P,0.05 by the Student t test).
doi:10.1371/journal.pone.0069296.g005
RYR1 Mutation Causing Variable Phenotype
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e69296
the normalization of RyR1 and DHPRalpha 1.1 expression levels,
attesting the veracity of results (Fig 5).
Discussion
In the present report we performed genome wide linkage
analysis of a large consanguineous family suffering from an
autosomal recessive atypical and heterogeneous congenital myop-
athy. Our results identified a single homozygous missense
mutation in the RYR1 gene which leads to depletion of the
RyR1 protein and of the DHPRa1 in muscle.
The RyR1 protein functions as the sarcoplasmic reticulum
calcium release channel and also connects the sarcoplasmic
reticulum and transverse tubules [4]. Mutations within this gene
have been associated with several phenotypes including malignant
hyperthermia susceptibility (MHS), central core disease (CCD),
and multi-minicore myopathy (MmD) with external ophthalmo-
plegia [16,17]. More recently, several additional atypical RYR1-
related myopathies have been reported [3,20–22].
The phenotype observed in this family was consistent with
congenital myopathy regarding early onset of muscle weakness
and absence of degeneration/regeneration on muscle biopsies.
Furthermore, histopathological studies revealed fiber-size variation
and internally-displaced nuclei which have been described in
RYR1 related centronuclear myopathies [3,20] (CNM). Interest-
ingly, other aspects characteristic of autosomal recessive RYR1
related myopathies, such as the presence of cores and ocular
involvement, were not present. These histopathological variabil-
ities have been previously reported and discussed in a few cases
[3,20,23,24]. Specifically, Quinlivan et al [25] described 3 patients
with dominant RYR1 CCD where cores were absent in the
youngest index case. They suggested an age effect with probable
core appearance on later biopsies. The absence of ocular
involvement in autosomal recessive mutations is rare but has
been recently described by several clinicians [3,20].
Several molecular mechanisms have been proposed explaining
the mutations’ effect on RyR1 function (see [17,26] for review):
leaky channels and voltage sensor uncoupled channels for CCD
[10,26–30], hypersensitive channels for MHS [31,32], low RyR1
expression/content for MmD [9,33,34], CFTD [21] and CNM
[3,20]. Interestingly, western blot analysis demonstrated a drastic
reduction in the amount of RyR1 protein in these patients’ muscle
biopsy. Importantly, this reduction was not paralleled by a
reduced content of RYR1 transcript as demonstrated by qRT-PCR
using MYH1 as an internal control (data not shown). However, it
was accompanied by a significant reduction in DHPRalpha1
content as evidenced by western blotting. As far as functionality,
using the EBV-immortalized cell model, we saw no effect of the
mutation on the sensitivity of the RyR1 to pharmacological
activation, though the presence of the mutation was accompanied
by a slight decrease in the resting [Ca2+] as well as a reduced peak
[Ca2+] release at high concentrations (.750 mM) of the RyR1
agonist 4-chloro-m-cresol. Since, the difference in 4-chloro-m-
cresol-induced Ca2+ release was noted only for concentrations
.750 mM its biological significance is difficult to explain, as is the
decrease in resting [Ca2+] which would indicate a possible
compensatory mechanism by proteins involved in lowering the
resting [Ca2+], such as the CaATPases and /or the Na/Ca2+
exchanger.
Many patients with autosomal recessive RYR1 related myopa-
thies described in the literature have a genetic background
characterized by compound heterozygous mutations, more spe-
cifically a missense mutation on one allele and a null mutation on
the other [3,19]. This could explain at least in part, the observed
decrease in RyR1 protein observed in such families. However, in
the present study we identified a homozygous missense mutation.
The substituted residue is highly conserved among the different
species and RyR1 isoforms and localized within a cytoplasmic
domain which has been found to interact with apocalmodulin [35]
and the II–III loop of the alpha 1 subunit of the DHPR involved in
retrograde signaling [36].
It is worth mentioning that besides the p.Y3016C mutation, all
affected members investigated in the present report harbor the
p.G2060C polymorphism at the homozygous state. This poly-
morphism has been previously described as having a potential
effect on the level of RyR1 protein [33]. All the members of the
pedigree have been investigated for this polymorphism and
individual IV.22 is homozygous for p.G2060C and healthy. This
finding is important as it confirms that, when present alone, this
variant is not pathogenic; indeed studies on intracellular Ca2+
homeostasis did not reveal any differences in resting Ca2+,
thapsigargin-sensitive intracellular stores and sensitivity to 4-
chloro-m-cresol in cells carrying the p.G2060C substitution and
controls (results not shown). However we suggest that in
association with other variants such as the p.Y3016C, the presence
of the p.G2060C may worsen the myopathic phenotype. It would
have been interesting to study the RyR1 protein level on
individual IV.22 biopsy, unfortunately it was not available.
In this report we present 4 patients from an extended family
with a recessive myopathy related to the p.Y3016C homozygous
missense mutation in the RYR1. This mutation results in depletion
of the RyR1 protein as well as depletion of the DHPRa1 protein.
Several atypical features characterize this family. Two different
phenotypes were noted in patients carrying the same homozygous
mutation. One patient had neonatal onset of weakness, was never
ambulatory and had central nuclei on muscle biopsy. Such
presentation of centronuclear myopathy related to recessive RYR1
mutation has been previously described [3,20]. On the other hand,
three other patients had milder initial presentation and slowly
progressive muscle weakness and were still walking at the age of
17 years (patient 2), 10 years (patient 3) and 9 years (patient 4).
Their muscle biopsy did not show any cores, but focal areas of
fibrosis were noted. The slowly progressive course, absence of
morphological sarcomere abnormalities and accumulation of
fibrosis was originally interpreted as muscular dystrophy in these
patients. Moreover no ocular involvement typical to recessive
RYR1 mutations was noted in any of the 4 patients.
This new RYR1 mutation emphasizes the fact that decrease in
RyR1 expression can cause heterogeneous clinical presentation in
the same family, including slowly progression course without
central cores on muscle biopsy. Therefore RYR1 related myopathy
should be considered in wide variety of clinical and pathological
presentation in childhood myopathies.
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